Results 11 to 20 of about 12,716 (134)

High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis [PDF]

Blood, 2017
Key Points Some 10.1% of adults with non–Langerhans cell histiocytosis have a concomitant myeloid neoplasm with each often harboring distinct mutations. The presence of distinct kinase mutations in histiocytosis and myeloid neoplasms resulted in discordant responses to targeted therapy.
Papo, Matthias, Diamond, Eli, Cohen-Aubart, Fleur, Emile, Jean-François, Roos-Weil, Damien, Gupta, Nishant, Durham, Benjamin, Ozkaya, Neval, Dogan, Ahmet, Ulaner, Gary, Rampal, Raajit, Kahn, Jean-Emmanuel, Sené, Thomas, Charlotte, Frédéric, Hervier, Baptiste, Besnard, Caroline, Bernard, Olivier, Settegrana, Catherine, Droin, Nathalie, Hélias-Rodzewicz, Zofia, Amoura, Zahir, Abdel-Wahab, Omar, Haroche, Julien   +22 more
semanticscholar   +6 more sources

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis

Blood Advances, 2023
Abstract Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) are rare non-Langerhans cell histiocytoses (non-LCHs), for which therapeutic options are limited. MAPK pathway activation through BRAFV600E mutation or other genomic alterations is a histiocytosis hallmark and correlates with a favorable response to BRAF inhibitors ...
Ashley Aaroe, Razelle Kurzrock, Gaurav Goyal, Aaron M. Goodman, Harsh Patel, Gordon Ruan, Gary Ulaner, Jason Young, Ziyi Li, Derek Dustin, Ronald S. Go, Eli L. Diamond, Filip Janku   +12 more
semanticscholar   +4 more sources

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis [PDF]

Molecular Cancer Therapeutics, 2019
Abstract The BRAFV600E mutation and BRAF inhibitor responsiveness characterize ∼50% of patients with the non-Langerhans cell histiocytosis (non-LCH) Erdheim–Chester disease (ECD). We interrogated the non-LCH molecular landscape [ECD, n = 35; Rosai–Dorfman disease (RDD), n = 3; mixed ECD/RDD, n = 1] using BRAFV600E PCR and/or next ...
Janku, Filip, Diamond, Eli L, Goodman, Aaron M, Raghavan, Vaijayanthi Kandadai, Barnes, Tamara G, Kato, Shumei, Abdel-Wahab, Omar, Durham, Benjamin H, Meric-Bernstam, Funda, Kurzrock, Razelle   +9 more
semanticscholar   +6 more sources

Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α

Blood, 2005
AbstractErdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement. To date, there is no standard treatment for this disorder, and more than half of the patients succumb within 3 years. Because interferon-α promotes the terminal differentiation of histiocytes and dendritic cells, we hypothesized that this molecule would
Bita Esmaeli, Razelle Kurzrock, Razelle Kurzrock, Razelle Kurzrock, Cynthia Boxrud, Cynthia Boxrud, Cynthia Boxrud, Fadi Braiteh   +7 more
semanticscholar   +5 more sources

Disseminated non-Langerhans cell histiocytosis with an IRF2BP2-NTRK1 gene fusion identified by next-generation sequencing [PDF]

JAAD Case Reports, 2020
Beth A. Martin, Warren H. Chan, Ryanne A. Brown, Aatman Shah, Caely Hambro, Gordon H. Bae, Bernice Y. Kwong, Roberto A. Novoa   +7 more
semanticscholar   +6 more sources

Non‐Langerhans cell histiocytosis xanthogranuloma patient with varying histopathology leading to progressive nodular histiocytosis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2021
restriction
Jemin Kim, Yeongjoo Oh, Chang Ook Park
openaire   +5 more sources

Case report: Pulmonary non-Langerhans cell histiocytosis in a dog with acute interstitial granulomatous pneumonia

Frontiers in Veterinary Science
BackgroundPulmonary involvement of Non-Langerhans Cell Histiocytosis (PNLCH) is a rare cause of interstitial pulmonary disease in people and are classified as either Erdheim-Chester disease (ECD) or Rosai-Dorfman disease (RDD). In veterinary medicine, feline pulmonary Langerhans cell histiocytosis (PLCH) has been identified as an infiltrative ...
Kyle L. Granger, Kurt Williams, Alex Ohlendorf, Sarah Shropshire, Kelly E. Hall   +4 more
openaire   +4 more sources

A RARE CASE OF PULMONARY NON-LANGERHANS CELL HISTIOCYTOSIS [PDF]

Chest, 2020
Kristen Hughes, Emad Shehada, Bernadette Schmidt, Victoria Gonzalez   +3 more
openaire   +3 more sources

Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review

Human Pathology: Case Reports, 2019
Langerhans Cell Histiocytosis (LCH) and the non-LCH, Erdheim Chester Disease, are rare histiocytic neoplasms with distinctive clinical and immunophenotypic features, but with several overlapping molecular features. LCH is a neoplasm of Langerin-positive, CD1a-positive, S100-positive dendritic cells (DCs), once thought to arise from the epidermal or ...
Liqiang Xi, Laura M. Wake, Elaine S. Jaffe, Mark Raffeld   +3 more
openaire   +4 more sources

NON-LANGERHANS CELLS HISTIOCYTOSIS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS - CASE REPORT

SBR 2021 Congresso Brasileiro de Reumatologia, 2021
Edgard Torres dos Reis Neto, Rodrigo Lorenzetti Serrano, Izaura Tereza Silva Guedes, Renan Rodrigues Neves Ribeiro do Nascimento, João Paulo Peres Lima, Isaac Felipe Leite Braz, Felipe de Lacerda Veiga, Leonardo Afonso Costa, Guilherme Pereira Carlesso, Miriam Fang Castro, Lucas de Castro Barroti   +10 more
openaire   +2 more sources